Effects of decreased preoperative endotoxin core antibody levels on long-term mortality after coronary artery bypass graft surgery

Archives of Surgery

Volumn 141, Issue 7, 2006, Pages 637-641

  Moretti, Eugene W ^a   Newman, Mark F ^a   Muhlbaier, Lawrence H ^a   Whellan, David ^a,c   Petersen, Rebecca P ^a   Rossignol, Daniel ^b   McCants Jr , Charles B ^a   Phillips Bute, Barbara ^a   Bennett Guerrero, Elliott ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b EISAI INC   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; ENDOTOXIN ANTIBODY; GLYCERYL TRINITRATE; IMMUNOGLOBULIN M;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DEATH; FEMALE; FOLLOW UP; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; STATISTICAL ANALYSIS; SURVIVAL RATE;

BIOLOGICAL MARKERS; CORONARY ARTERY BYPASS; CORONARY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TIME FACTORS;

EID: 33746096560     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.141.7.637     Document Type: Article

References (53)

1. American Heart Association. Heart disease and stroke statistics: 2005 update. http://www.americanheart.org. Accessed December 31, 2003.
2. Hammermeister KE, Burchfiel C, Johnson R, Grover FL. Identification of patients at greatest risk for developing major complications at cardiac surgery. Circulation. 1990;82(suppl 5):IV380-IV389.
3. Goris RJ, te Boekhorst TP, Nuytinck JK, Gimbrere JS. Multiple-organ failure: generalized autodestructive inflammation? Arch Surg. 1985;120:1109-1115.
4. Bone RC, Balk RA, Cerra FB, et al; ACCP/SCCM Consensus Conference Committee, American College of Chest Physicians/Society of Critical Care Medicine. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992;101:1644-1655.
5. Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parillo JE. Endotoxemia in human septic shock. Chest. 1991;99:169-175.
6. Rush BF Jr, Sori AJ, Murphy TF, Smith S, Flanagan JJ Jr, Machiedo GW. Endotoxemia and bacteremia during hemorrhagic shock: the link between trauma and sepsis? Ann Surg. 1988;207:549-554.
7. Suffredini AF, Fromm RE, ParkerMM,et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 1989;321:280-287.
8. Bjork J, Hugli TE, Smedegard G. Microvascular effects of anaphylatoxins C3a and C5a. J Immunol. 1985;134:1115-1119.
9. Morrison DC, Cochrane CG. Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins). J Exp Med. 1974;140:797-811.
10. Barclay GR. Bacterial Endotoxins: Lipopolysaccharides From Genes to Therapy. New York, NY: John Wiley & Sons; 1995.
11. Poxton IR. Antibodies to lipopolysaccharide. J Immunol Methods. 1995;186:1-15.
12. Baumgartner JD. Immunotherapy with antibodies to core lipopolysaccharide: a critical appraisal. Infect Dis Clin North Am. 1991;5:915-927.
13. Bennett-Guerrero E, Panah MH, Barclay GR, et al. Decreased endotoxin immunity is associated with greater mortality and/or prolonged hospitalization after surgery. Anesthesiology. 2001;94:992-998.
14. Bennett-Guerrero E, Ayuso L, Hamilton-Davies C, et al. Relationship of preoperative antiendotoxin core antibodies and adverse outcomes following cardiac surgery. JAMA. 1997;277:646-650.
15. Mathew JP, Grocott HP, Phillips-Bute B, et al. Lower endotoxin immunity predicts increased cognitive dysfunction in elderly patients after cardiac surgery. Stroke. 2003;34:508-513.
16. Hamilton-Davies C, Barclay GR, Cardigan RA, et al. Relationship between preoperative endotoxin immune status, gut perfusion, and outcome from cardiac valve replacement surgery. Chest. 1997;112:1189-1196.
17. Bennett-Guerrero E, Barclay GR, Youssef ME, et al. Exposure to bacteroides fragilis endotoxin during cardiac surgery. Anesth Analg. 2000;90:819-823.
18. Mythen MG, Barclay GR, Purdy G, et al. The role of endotoxin immunity, neutrophil degranulation and contact activation in the pathogenesis of postoperative organ dysfunction. Blood Coagul Fibrinolysis. 1993;4:999-1005.
19. Windsor JA, Fearon KC, Ross JA, et al. Role of serum endotoxin and antiendotoxin core antibody levels in predicting the development of multiple organ failure in acute pancreatitis. Br J Surg. 1993;80:1042-1046.
20. Andersen LW, Baek L, Degn H. Presence of circulating endotoxin during cardiac operations. J Thorac Cardiovasc Surg. 1987;93:115-119.
21. Parsonnet V, Dean D, Bernstein AD. A method of uniform stratification of risk for evaluating the results of surgery in acquired adult heart disease. Circulation. 1989;79:I3-I12.
22. Califf RM, Harrell FE Jr, Lee KL, et al. The evolution of medical and surgical therapy for coronary artery disease: a 15-year perspective. JAMA. 1989;261:2077-2086.
23. Jones RH, Kesler K, Phillips HR III, et al. Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery disease. J Thorac Cardiovasc Surg. 1996;111:1013-1025.
24. Mark DB, Nelson CL, Califf RM, et al. Continuing evolution of therapy for coronary artery disease: initial results from the era of coronary angioplasty. Circulation. 1994;89:2015-2025.
25. Califf RM, DeLong ER, Ostbye T, et al. Underuse of aspirin in a referral population with documented coronary artery disease. Am J Cardiol. 2002;89:653-661.
26. Luca R, Lijnen HR, Suffredini AF, et al. Increased angiostatin levels in bronchoalveolar lavage fluids from ARDS patients and from human volunteers after lung instillation of endotoxin. Thromb Haemost. 2002;87:966-971.
27. O'Grady NP, Preas HL, Pugin J, et al. Local inflammatory responses following bronchial endotoxin instillation in humans. Am J Respir Crit Care Med. 2001;163:1591-1598.
28. Suffredini AF, Fromm RE, Parker MM, et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 1989;321:280-287.
29. Martich GD, Boujoukos AJ, Suffredini AF. Response of man to endotoxin. Immunobiology. 1993;187:403-416.
30. Rothenburger M, Soeparwata R, Deng MC, et al. The impact of anti-endotoxin core antibodies on endotoxin and cytokine release and ventilation time after cardiac surgery. J Am Coll Cardiol. 2001;38:124-130.
31. Strutz F, Heller G, Krasemann K, Krone B, Muller GA. Relationship of antibodies to endotoxin core to mortality in medical patients with sepsis syndrome. Intensive Care Med. 1999;25:435-444.
32. Mangano DT, Layug EL, Wallace A, Tateo I; Multicenter Study of Perioperative Ischemia Research Group. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. N Engl J Med. 1996;335:1713-1720.
33. Poldermans D, Boersma E, Bax JJ, et al; Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N Engl J Med. 1999;341:1789-1794.
34. Landesberg G, Shatz V, Akopnik I, et al. Association of cardiac troponin, CK-MB, and postoperative myocardial ischemia with long-term survival after major vascular surgery. J Am Coll Cardiol. 2003;42:1547-1554.
35. DeCamp MM, Demling RH. Posttraumatic multisystem organ failure. JAMA. 1988;260:530-534.
36. Moore FA, Moore EE, Poggetti R, et al. Gut bacterial translocation via the portal vein: a clinical perspective with major torso trauma. J Trauma. 1991;31:629-636.
37. Ford EG, Baisden CE, Matteson ML, Picone AL. Sepsis after coronary bypass grafting: evidence for loss of the gut mucosal barrier. Ann Thorac Surg. 1991;52:514-517.
38. Buller HR, ten Cate JW, Sturk A, Thomas LL. Validity of the endotoxin assay in post surgical patients. Prog Clin Biol Res. 1985;189:405-417.
39. Munster AM, Smith-Meek M, Dickerson C, Winchurch RA. Translocation: incidental phenomenon or true pathology? Ann Surg. 1993;218:321-326.
40. Bion JF, Badger I, Crosby HA, et al. Selective decontamination of the digestive tract reduces gram-negative pulmonary colonization but not systemic endotoxemia in patients undergoing elective liver transplantation. Crit Care Med. 1994;22:40-49.
41. Deitch EA, Morrison J, Berg R, Specian RD. Effect of hemorrhagic shock on bacterial translocation, intestinal morphology, and intestinal permeability in conventional and antibiotic-decontaminated rats. Crit Care Med. 1990;18:529-536.
42. Giamarellou-Bourboulis EJ, Perdios J, Lelekis M, Eoconomou E, Tsouroulas P, Giamarellou H. Impact of cefuroxime administration on endotoxin (LPS) and tumour necrosis factor-α (TNFα) blood levels in patients suffering from acute pyelonephritis: a preliminary report. Int J Antimicrob Agents. 1999;11:115-119.
43. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al; HA-1A Sepsis Study Group. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N Engl J Med. 1991;324:429-436.
44. Greenman RL, Schein RM, Martin MA, et al; XOMA Sepsis Study Group. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA. 1991;266:1097-1102.
45. Warren HS, Amato SF, Fitting C, et al. Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J Exp Med. 1993;177:89-97.
46. Brade L, Engel R, Christ WJ, Rietschel ET. A nonsubstituted primary hydroxyl group in position 6' of free lipid A is required for binding of lipid A monoclonal antibodies. Infect Immun. 1997;65:3961-3965.
47. Mullarkey M, Rose JR, Bristol J, et al. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther. 2003;304:1093-1102.
48. Lynn M, Rossignol DP, Wheeler JL, et al. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis. 2003;187:631-639.
49. Rossignol DP, Lynn M. Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue. J Endotoxin Res. 2002;8:483-488.
50. Gordon BR, Parker TS, Levine DM, et al. Safety and pharmacokinetics of an endotoxin-binding phospholipid emulsion. Ann Pharmacother. 2003;37:943-950.
51. Woo YJ, Taylor MD, Cohen JE, et al. Ethyl pyruvate preserves cardiac function and attenuates oxidative injury after prolonged myocardial ischemia. J Thorac Cardiovasc Surg. 2004;127:1262-1269.
52. Sappington PL, Fink ME, Yang R, Delude RL, Fink MP. Ethyl pyruvate provides durable protection against inflammation-induced intestinal epithelial barrier dysfunction. Shock. 2003;20:521-528.
53. Rossignol DP, Wasan KM, Choo E, et al. Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers. Antimicrob Agents Chemother. 2004;48:3233-3240.